@prefix dcterms: .
@prefix this: .
@prefix sub: .
@prefix beldoc: .
@prefix rdfs: .
@prefix rdf: .
@prefix xsd: .
@prefix dce: .
@prefix pav: .
@prefix np: .
@prefix belv: .
@prefix prov: .
@prefix go: .
@prefix RNA: .
@prefix hgnc: .
@prefix geneProductOf: .
@prefix obo: .
@prefix occursIn: .
@prefix species: .
@prefix pubmed: .
@prefix orcid: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
sub:_1 geneProductOf: hgnc:1583;
a RNA: .
sub:_2 occursIn: obo:UBERON_0000945, species:9606;
rdf:object sub:_1;
rdf:predicate belv:decreases;
rdf:subject go:0006306;
a rdf:Statement .
sub:assertion rdfs:label "bp(GOBP:\"DNA methylation\") -| r(HGNC:CCND2)" .
}
sub:provenance {
beldoc: dce:description "Approximately 61,000 statements.";
dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
dce:title "BEL Framework Large Corpus Document";
pav:authoredBy sub:_4;
pav:version "20131211" .
sub:_3 prov:value "Treatment of cyclin D2-negativecells lines harboring promoter hypermethylation with demethylating agent,5-Aza-2'-deoxycytidine, led to a reactivation of cyclin D2 expression.These results suggest that DNA hypomethylation is a mechanism underlying theincreased expression of cyclin D2 in cancer cells";
prov:wasQuotedFrom pubmed:14612939 .
sub:_4 rdfs:label "Selventa" .
sub:assertion prov:hadPrimarySource pubmed:14612939;
prov:wasDerivedFrom beldoc:, sub:_3 .
}
sub:pubinfo {
this: dcterms:created "2014-07-03T14:32:11.989+02:00"^^xsd:dateTime;
pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}